General information on drug use in pregnancy
A drug can have more than one harmful effect on the fetus. Individual effects depend on the time of fetal exposure to the drug.
During the first 2 weeks after fertilisation and before full implantation, the embryo is thought to be resistant to any teratogenic effects of drugs. This is because there is no direct communication between the tissues of a pregnant person and an embryo until after the placenta starts to form.
The critical period for teratogenic effects is during organogenesis. This starts at about 17 days after conception and is complete by 60 to 70 days. Exposure to certain drugs during this period (17 to 70 days) can cause major birth defects.
Some drugs can interfere with functional development of organ systems (eg central nervous system, integumentary system, cardiovascular system) in the second and third trimesters and produce serious consequences.
A person may not be aware of their pregnancy until after the early stages of organogenesis. For this reason, drugs in the most severe category of risk (X in the Australian categorisation of drugs in pregnancy) should not be prescribed to anyone who could become pregnant, unless a pregnancy test is negative and they are using an effective method of contraception.
However, there are conditions in which a person who could become pregnant will require long-term medication despite known harms of the drugs. At the time of initial prescribing in any such situation, the prescriber should discuss the importance of reviewing medication requirements well before conception. For some conditions, it may be possible to change to a different category of drug. If a person becomes pregnant while on medication and there has been no opportunity for earlier discussion with the prescriber, their medication should be reviewed as soon as possible.
The following checklist may assist in deciding whether to prescribe a particular drug during pregnancy:
- Nonpharmacological treatment: Is such a treatment available and likely to be successful? Would such treatment be reasonable at least until the first trimester is complete? Most people who are pregnant strongly favour this type of treatment and concordance is likely to be high.
- Harm–benefit analysis (see also Potential benefits and harms to the patient and fetus associated with psychotropic use during pregnancy for psychotropic drugs): For the particular drug under consideration, what are the potential harms and benefits to the pregnant person and harms to the fetus of prescribing? What are the harms and benefits (for each) of not prescribing?
- Incidence of spontaneous congenital abnormality: When drugs cannot be avoided, it may be appropriate to discuss the incidence of non–drug-related spontaneous abnormalities. This is often underestimated. In Australia, the incidence of significant congenital abnormality is 2 to 4% of live births, and minor abnormalities are recognised in approximately 15% of newborns.
- Education, documentation and communication: Has the education of the person and, with their permission, their significant others (eg partner, family, friends) regarding harms and benefits been properly documented in the patient's notes? Have those health professionals involved in obstetric management been informed? It may be appropriate to discuss the use of, and limitations of, available antenatal screening to detect abnormalities in the fetus. The person, with or without their significant others, will need to give some consideration to the consequences of an abnormal result.
Routine review later in the pregnancy includes consideration of dose alteration during delivery to avoid neonatal problems such as respiratory depression.